KEGG   DRUG: CatumaxomabHelp
Entry
D09207                      Drug                                   

Name
Catumaxomab (INN);
Removab (TN)
Remark
ATC code: L01XC09
Efficacy
Antineoplastic, Anti-CD3 antibody, Anti-EpCAM antibody
  Disease
Malignant ascites
Comment
Monoclonal antibody
Target
EPCAM (CD326) [HSA:4072] [KO:K06737]
CD3 [HSA:915 916 917] [KO:K06450 K06451 K06452]
  Pathway
hsa04640  Hematopoietic cell lineage
hsa04660  T cell receptor signaling pathway
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC09 Catumaxomab
      D09207  Catumaxomab (INN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Cell adhesion molecules: Ig superfamiy
   CAMs
    EPCAM (CD326)
     D09207  Catumaxomab (INN)
  Other cell surface molecules
   CD molecules
    CD3
     D09207  Catumaxomab (INN)
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09207
BRITE hierarchy
Other DBs
CAS: 509077-98-9
PubChem: 96025887

» Japanese version   » Back

DBGET integrated database retrieval system